NCT05085665

Loiasis Cross-reactive Antigenemia and Treatment-related Adverse Events

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 41 (actual)
• Sponsor: Washington University School of Medicine · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Accepted

Summary

This study seeks to determine which Loa loa antigens are released into circulation when infected individuals are treated with ivermectin.

Detailed description

A cohort of up to 50 participants with Loa loa microfilarial levels between 5,000 and 18,000 per ml/blood will be treated with ivermectin in an inpatient setting. Participants will be monitored for treatment-related adverse events for seven days post-treatment, and will have blood drawn on days 0, 1, 2, 3, and 7 post-treatment to assess for microfilarial load, cytokine, and antigen levels.

Conditions

• Loiasis

Interventions

Type	Name	Description
DRUG	Ivermectin	single dose, 150 ug/kg

Timeline

• Start date: 2021-07-30
• Primary completion: 2021-08-31
• Completion: 2021-09-30
• First posted: 2021-10-20
• Last updated: 2022-09-29
• Results posted: 2022-09-29

Locations

1 site across 1 country: Cameroon

Regulatory

• FDA-regulated drug study